KRON News and Press, Kronos Bio Inc. From 04/11/23

Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by canc...

2023-03-15 17:06:40 ET Kronos Bio press release ( NASDAQ: KRON ): Q4 GAAP EPS of -$0.56 beats by $0.03 . With its ongoing and currently planned clinical programs and $247.9 million in cash, cash equivalents and investments as of December 31, 2022, the company anti...

First patient dosed in expansion portion of KB-0742 Phase 1/2 study, with initial efficacy results expected in 2H 2023 Recommended Phase 2 dose and initial data from Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML on track to report in Q4 2023 or Q1 ...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 43 rd Annual Cowen Health Care Conference, taking place March 6-8, 2023, i...

Penny Stocks, News, & Market Momentum This Week This is the first full week of the New Year and one that many investors will be focused on. Not only will we see Federal Reserve Chair Jerome Powell’s first major speech of the year, but there’s also no time wasted for the firs...

Kronos Bio will receive a $20 million upfront payment and could receive up to an additional $554 million in milestone payments Agreement will leverage Kronos Bio’s expertise in transcriptional regulatory networks and its proprietary drug discovery platform SAN MATEO, Calif. a...

Lanraplenib is being evaluated in ongoing Phase 1b/2 trial in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated AML Additional presentations highlight Kronos Bio’s collaboration with academic cooperative groups to better understand the predictive val...

Kronos Bio to move into Phase 2 stage of study, evaluating compound in patients with MYC-amplified and other transcriptionally addicted tumors Data demonstrate achievement of target engagement goal, differentiated pharmacokinetic profile and long half-life Detailed results fro...

Kronos Bio press release ( NASDAQ: KRON ): Q3 GAAP EPS of -$0.57 beats by $0.08 . With its ongoing and currently planned clinical programs and $270.3 million in cash, cash equivalents and investments as of September 30, 2022, the company anticipates sufficient res...

Earlier today, the company announced prioritization of clinical portfolio to focus on next-generation SYK inhibitor, lanraplenib and CDK9 inhibitor, KB-0742 $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, with expected cash runway into Q2 2025 ...